文献速递浆细胞疾病

A.R.R.O.W.2:每周一次与每周两次卡非佐米联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2024-01-01

这项开放标签、3期、多中心、随机研究纳入454例复发/难治性多发性骨髓瘤患者,1:1随机接受每周一次卡非佐米56 mg/m2联合来那度胺和地塞米松(KRd56)或每周两次卡非佐米27 mg/m2联合Rd(KRd27)。总缓解率分别为82.5%与86.3%(风险比0.954,95%CI 0.882-1.032),未达到非劣效性统计学阈值(P=0.0666)。作者认为尽管未达到ORR非劣效性统计学意义,每周一次KRd56的疗效和安全性相似,可能为有效且便利的治疗选择。

要点

  • 每周一次KRd56与每周两次KRd27的总缓解率分别为82.5%与86.3%,未达到非劣效性统计学阈值(P=0.0666)。
  • 完全缓解或更好比例分别为46.9%与36.3%,达到完全缓解且微小残留病阴性比例分别为21.5%与18.1%。
  • 无进展生存期两组相当(风险比0.945,95%CI 0.617-1.447),安全性特征相似。

核心结论

  • 尽管ORR非劣效性未达到统计学意义,每周一次KRd56的疗效和安全性相似于每周两次KRd27,每周一次KRd56可能为复发/难治性多发性骨髓瘤患者提供有效且便利的治疗选择。

研究设计与样本

  • 开放标签、3期、多中心、随机研究,共454例复发/难治性多发性骨髓瘤患者按1:1随机分组。
  • 每周一次组(KRd56;n=228)接受卡非佐米56 mg/m2每周一次30分钟输注联合来那度胺和地塞米松。
  • 每周两次组(KRd27;n=226)接受卡非佐米27 mg/m2每周两次10分钟输注联合来那度胺和地塞米松。
  • 两组基线特征均衡。
  • 试验注册号:NCT03859427。

主要发现

  • 总缓解率:每周一次组82.5%(95%CI 76.9-87.2)vs 每周两次组86.3%(95%CI 81.1-90.5),风险比0.954(95%CI 0.882-1.032),未达到非劣效性统计学阈值(P=0.0666)。
  • 完全缓解或更好:每周一次组46.9% vs 每周两次组36.3%。
  • 达到完全缓解且微小残留病阴性:每周一次组21.5% vs 每周两次组18.1%(比值比1.235,95%CI 0.775-1.970)。
  • 无进展生存期两组相当(风险比0.945,95%CI 0.617-1.447)。
  • 两组安全性特征相似。

关键数值与推荐

  • 每周一次卡非佐米56 mg/m2联合来那度胺和地塞米松(KRd56)与每周两次卡非佐米27 mg/m2联合Rd(KRd27)进行比较。
  • 非劣效性主要终点为总缓解率(ORR)。

临床怎么用

  • 作者认为每周一次KRd56可能为复发/难治性多发性骨髓瘤患者提供有效且便利的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dimopoulos MA, Coriu D, Delimpasi S, et al. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Blood Adv. 2024. PMID: 39024542. doi:10.1182/bloodadvances.2024013101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。